Chemical modification of bradykinin-polymer conjugates for optimum delivery of nanomedicines to tumors
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
38460653
DOI
10.1016/j.nano.2024.102744
PII: S1549-9634(24)00013-3
Knihovny.cz E-resources
- Keywords
- Bradykinin, Controlled release, HPMA polymer, Hydrazone, Tumor,
- MeSH
- Bradykinin MeSH
- Doxorubicin chemistry MeSH
- Hydrogen-Ion Concentration MeSH
- Mice MeSH
- Tumor Microenvironment MeSH
- Neoplasms * drug therapy MeSH
- Nanomedicine MeSH
- Polymers * chemistry MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Bradykinin MeSH
- Doxorubicin MeSH
- Polymers * MeSH
We recently prepared pH-responsive HPMA copolymer conjugates of bradykinin (P-BK), which release BK in response to the acidic tumor microenvironment, and found that administration of P-BK increased the tumor accumulation and therapeutic efficacy of nanomedicine. Because the release of BK from P-BK determines its onset of action, P-BKs with different release rates were prepared, and their properties were evaluated. The release kinetics were significantly altered by substitution proximal to hydrazone bond, release constant of methyl-substituted P-BK (P-MeBK) was approximately 4- and 80-fold higher than that of cyclopropyl-substituted P-BK (P-CPBK) and phenyl-substituted P-BK (P-PhBK). None of the P-BKs were active, but the release of BK restored their BK-like activity. Pre-administration of the P-BKs increased the tumor accumulation of nanomedicine in C26 tumor-bearing mice by 2- and 1.4-fold for P-MeBK and P-PhBK at 3 and 6 h. Altogether, this study provides insights into the design of pH-responsive nanodrugs with the desired release properties to target acidic lesions such as cancer and inflammation.
References provided by Crossref.org